一种宿主酶通过使肠道脂多糖失活来减轻代谢功能障碍相关脂肪性肝病(MASLD)。

A host enzyme reduces metabolic dysfunction-associated steatotic liver disease (MASLD) by inactivating intestinal lipopolysaccharide.

作者信息

Wang Zhiyan, Ojogun Nore, Liu Yiling, Gan Lu, Xiao Zeling, Feng Jintao, Jiang Wei, Chen Yeying, Zou Benkun, Yu ChengYun, Li Changshun, Ashuo Asha, Li Xiaobo, Fu Mingsheng, Wu Jian, Chu Yiwei, Munford Robert S, Lu Mingfang

机构信息

Department of Immunology, School of Basic Medical Sciences, Department of Trauma-Emergency & Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.

Infectious Disease Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, United States.

出版信息

Elife. 2025 Apr 24;13:RP100731. doi: 10.7554/eLife.100731.

Abstract

The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been increasing worldwide. Since gut-derived bacterial lipopolysaccharides (LPS) can travel via the portal vein to the liver and play an important role in producing hepatic pathology, it seemed possible that (1) LPS stimulates hepatic cells to accumulate lipid, and (2) inactivating LPS can be preventive. Acyloxyacyl hydrolase (AOAH), the eukaryotic lipase that inactivates LPS and oxidized phospholipids, is produced in the intestine, liver, and other organs. We fed mice either normal chow or a high-fat diet for 28 weeks and found that mice accumulated more hepatic lipid than did mice. In young mice, before increased hepatic fat accumulation was observed, mouse livers increased their abundance of sterol regulatory element-binding protein 1, and the expression of its target genes that promote fatty acid synthesis. mice also increased hepatic expression of and , which mediate fatty acid uptake, and decreased expression of fatty acid-oxidation-related genes and . Our results provide evidence that increasing AOAH abundance in the gut, bloodstream, and/or liver may be an effective strategy for preventing or treating MASLD.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)的发病率在全球范围内一直在上升。由于源自肠道的细菌脂多糖(LPS)可通过门静脉进入肝脏,并在肝脏病理形成中起重要作用,因此似乎有可能:(1)LPS刺激肝细胞积累脂质,以及(2)使LPS失活可能具有预防作用。酰氧基酰基水解酶(AOAH)是一种使LPS和氧化磷脂失活的真核脂肪酶,在肠道、肝脏和其他器官中产生。我们给小鼠喂食普通饲料或高脂饮食28周,发现[此处原文似乎有缺失信息]小鼠比[此处原文似乎有缺失信息]小鼠积累了更多的肝脏脂质。在年轻小鼠中,在观察到肝脏脂肪积累增加之前,[此处原文似乎有缺失信息]小鼠肝脏中固醇调节元件结合蛋白1的丰度增加,以及其促进脂肪酸合成的靶基因的表达增加。[此处原文似乎有缺失信息]小鼠还增加了介导脂肪酸摄取的[此处原文似乎有缺失信息]和[此处原文似乎有缺失信息]的肝脏表达,并降低了脂肪酸氧化相关基因[此处原文似乎有缺失信息]和[此处原文似乎有缺失信息]的表达。我们的结果提供了证据,表明增加肠道、血液和/或肝脏中AOAH的丰度可能是预防或治疗MASLD的有效策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8aa/12021412/20008e3d3e8c/elife-100731-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索